Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ONCOGENEX PHARMACEUTICALS Inc OGXI

Healthcare Biotechnology
"OncoGenex Pharmaceuticals Inc is a biopharmaceutical company focused on the development of cancer treatment resistance. It has developed Apatorsen to block the production of heat shock protein 27, or Hsp27, that promotes treatment resistance in cancer."

Recent & Breaking News (NDAQ:OGXI)

OncoGenex Announces Update on Phase 3 AFFINITY Trial Evaluating Custirsen in Men with Metastatic Castrate-Resistant Prostate Cancer

PR Newswire January 16, 2015

OncoGenex to Regain Rights to Custirsen from Teva

Canada NewsWire December 30, 2014

OncoGenex Announces Results from the Phase 2 Borealis-1(TM) Trial of Apatorsen in the Treatment of Metastatic Bladder Cancer

Canada NewsWire December 19, 2014

OncoGenex Announces Completion of Patient Enrollment in the Rainier(TM) Clinical Trial Evaluating Apatorsen in Combination with ABRAXANE® plus Gemcitabine in Patients with Metastatic Pancreatic Cancer

Canada NewsWire December 16, 2014

OncoGenex Pharmaceuticals to Present at the Stifel 2014 Healthcare Conference

Canada NewsWire November 17, 2014

OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2014

Canada NewsWire October 30, 2014

OncoGenex to Report Financial Results for Third Quarter 2014 on October 30, 2014

PR Newswire October 16, 2014

OncoGenex Announces Completion of Patient Enrollment in the Phase 3 AFFINITY Trial of Custirsen in Combination with Cabazitaxel/Prednisone as Second-line Chemotherapy in Men with Metastatic Castrate-Resistant Prostate Cancer

Canada NewsWire September 16, 2014

OncoGenex Announces Update on Phase 3 ENSPIRIT Trial Evaluating Custirsen in Advanced Non-Small Cell Lung Cancer

Canada NewsWire August 21, 2014

OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2014

Canada NewsWire August 7, 2014

OncoGenex Pharmaceuticals Announces Appointment of John A. Bencich as Vice President and Chief Financial Officer

Canada NewsWire August 7, 2014

OncoGenex to Report Financial Results for Second Quarter 2014 on August 7, 2014

Canada NewsWire July 24, 2014

OncoGenex Announces Cedar(TM) Clinical Trial Evaluating Apatorsen in Combination with Chemotherapy in Advanced Squamous Cell Lung Cancer is Now Open for Enrollment

Canada NewsWire July 1, 2014

OncoGenex Pharmaceuticals Announces Pricing of $24 Million Underwritten Registered Direct Offering

Canada NewsWire June 26, 2014

OncoGenex Pharmaceuticals, Inc. Reports Financial Results for First Quarter 2014

Canada NewsWire April 30, 2014

OncoGenex to Report Financial Results for First Quarter 2014 on April 30, 2014

Canada NewsWire April 28, 2014

OncoGenex Announces Top-Line Survival Results of Phase 3 SYNERGY Trial Evaluating Custirsen for Metastatic Castrate-Resistant Prostate Cancer

Canada NewsWire April 28, 2014

Teva and OncoGenex Announce Top-Line Survival Results of Phase III SYNERGY Trial Evaluating Custirsen in Combination with First-line Docetaxel and Prednisone for Metastatic Castrate-Resistant Prostate Cancer

Business Wire April 28, 2014

OncoGenex to Report Financial Results for Fourth Quarter and Year-Ended 2013 on March 11, 2014

Canada NewsWire February 25, 2014

OncoGenex Announces Target Number of Events Reached in Phase 3 SYNERGY Trial of Custirsen in Metastatic Castrate-Resistant Prostate Cancer

PR Newswire February 11, 2014